Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis

Lin, Lina; Nong, Weixia; Luo, Bin; Ge, Yingying; Zeng, Xia; Li, Feng; Fan, Rong; Zhang, Qingmei; Xie, Xin

doi:10.1002/iid3.534

Cited by 5 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some poorly differentiated tumors, such as colorectal cancer, ovarian cancer, and glioma, were found to have higher OY-TES-1 expression than well-differentiated tumors or their adjacent tissues [ 10 , 11 , 15 ]. OY-TES-1 expression may be significantly higher in the tumors of ovarian cancer patients with shorter survival times and faster relapse than those with longer survival [ 24 , 25 ]. Higher expression of OY-TES-1 appears to be related to high cell proliferative activity, as supported by several in vitro experiments [ 17 , 18 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues

Zhang

et al. 2022

Journal of Healthcare Engineering

Self Cite

View full text Add to dashboard Cite

OY-TES-1 is reportedly involved in carcinogenesis and spermatogenesis. However, the tissue distribution of OY-TES-1 in the normal human body remains elusive. This study detected OY-TES-1 expression in human fetal and adult normal tissues by immunohistochemistry. We identified a general principle of OY-TES-1 expression. The expression of OY-TES-1 was found in neurons, smooth muscle cells, and cardiac muscle cells from both fetuses and adults. The connective tissue showed no specific staining throughout the fetal and adult samples. With OY-TES-1-positive staining of the epithelium irregular, OY-TES-1 was strongly expressed in the epithelium of the skin and bladder, as well as hepatocytes, pancreatic islets, and acinous cells during the fetal stage but was not detected in the postnatal period. In contrast to the epithelium of blood vessels, the fetal and adult central hepatic vein and glomeruli showed negative expression of the OY-TES-1 protein. Sex-dimorphism was observed in the distribution of OY-TES-1 in male and female germ cells. Collectively, our results indicate that OY-TES-1 is a member of the cancer-testis antigen and autoantigen, with tissue-specific and period-specific expression patterns, revealing potential contributions of OY-TES-1 to the diagnosis and therapeutic treatment for neoplasms and infertility.

show abstract

Section: Discussionmentioning

confidence: 99%

“…OY-TES-1 was expressed both in distinct tissues of the fetus and adult, which indicates its potential as an autoantigen. It is believed that high OY-TES-1 expression or expression outside the normal location should be regarded as ectopic and a target of immunoreaction [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues

Zhang

et al. 2022

Journal of Healthcare Engineering

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that CT23 is not only highly expressed in various tumors, but also presents detectable specific antibodies in the serum of tumor patients, while the serum of healthy individual is negative. 9 , 13–15 , 17 These results suggest that CT23 is immunogenic like many other CTAs. Therefore, in recent years, many scholars have explored the possibility of CT23 as a target for tumor immunotherapy.…”

Section: Discussionmentioning

confidence: 81%

“… 10 Some of experiments in vitro have confirmed that down-regulating CT23 can reduce cancer cell growth, prevent cancer cell migration and invasion, and elevate the expression of apoptosis-related proteins, thereby promoting cell apoptosis. 11 , 12 In patients with ovarian cancer, high expression of CT23 was associated with paclitaxel resistance, stage and chemotherapy sensitivity, shortened survival time and accelerated recurrence rate, 10 , 13 while in colorectal cancer patients, high expression of CT23 is also confirmed to be correlated with tumor invasion stage and histological grade. 15 Furthermore, the presence of CT23 antibodies in the serum of patients with various tumors, including ovarian cancer, colorectal cancer, liver cancer, and glioma, indicates that CT23 is immunogenic and can induce a specific immune response, 13–15 , 17 making it a potential diagnostic and therapeutic target in cancer.…”

Section: Introductionmentioning

confidence: 98%

Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23

Zeng,

Nong,

Zou

et al. 2023

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Cancer-testis antigen CT23 is a class of tumor-associated antigens (TAA) characterized by restricted expression in male germ cells and a variety of tumor tissues. Numerous studies have shown that CT23 is closely related to tumor cell viability, proliferation, metastasis and invasion. CT23 is immunogenic and can cause specific immune response in tumor patients. Therefore, it is considered to be one of the best target antigens for designing therapeutic tumor vaccines and T-cell-mediated tumor immunotherapy. In this study, we initially obtained seven HLA-A*0201-restricted CT23 epitope candidate peptides through the T cell epitope prediction program. Subsequently, a T2 cell binding assay revealed the potential binding of all candidate peptides with HLA-A2 molecules. Notably, peptide P7 (ALLVLCYSI) exhibited the highest affinity, as evidenced by a fluorescence index (FI) of 2.19. Dendritic cells (DCs) loaded with CT23 candidate peptide can stimulate CD8 + T cell activation and proliferation, and compared with other candidate peptides, candidate peptide P7 is superior. The cytotoxic T lymphocytes (CTLs) stimulated by the peptide P7 had killing effect on tumor cells (HLA-A*0201 + , CT23 + ), but no killing effect on tumor cells (HLA-A*0201 − , CT23 + ). The CTLs induced by the peptide P7 also had a specific killing effect on T2 cells bearing the peptide P7. In summary, our findings suggest that the CT23 peptide P7 (ALLVLCYSI) can induce immune responses and holds potential for tumor-specific CTL therapy.

show abstract

“…В соматических тканях были обнаружены лишь следы мРНК OY-TES-1, тогда как в различных опухолях мРНК этого гена обнаруживалась с высокой частотой. Изучена экспрессия OY-TES-1 в мезенхимальных стволовых клетках [5], в клетках гепатоцеллюлярной карциномы [6], при раке яичников [7], раке молочной железы [8], показано влияние OY-TES-1 на процессы клеточного роста, клеточную миграцию, апоптоз, митоз и пролиферацию раковых клеток [5][6][7]. Иммуногистохимические исследования (ИГХ) и метод полимеразной цепной реакции (ПЦР) продемонстрировали полное отсутствие экспрессии OY-TES-1 в тканях здорового кишечника, здоровой печени и циррозной печени [6,9].…”

Section: Introductionunclassified

mRNA of the <i>OY-TES-1</i> gene in peripheral blood and tumors in colorectal cancer

Hilal,

Novikov,

Yakimov

et al. 2023

Rossijskij bioterapevtičeskij žurnal

View full text Add to dashboard Cite

Background. One of the testicular cancer genes is the OY-TES-1 gene, which encodes a proacrosin-binding protein. This gene is known to be expressed in tumor cells.Aim. To determinate the detection frequency of OY-TES-1 matrix ribonucleic acid (mRNA) in the peripheral blood and tumor of patients with colorectal cancer (CRC) in comparison with the clinical features of the course of a disease in order to assess the potential monitoring significance of this indicator.Materials and methods. A method for determining the level of OY-TES-1 mRNA based on reverse transcription polymerase chain reaction (RT-PCR). The detection frequency of mRNA OY-TES-1 gene in blood and tumor samples of 66 patients with CRC, as well as the blood of healthy volunteers, was evaluated.Results. In the peripheral blood of healthy volunteers, no OY-TES-1 mRNA was detected. In the blood of CRC patients, OY-TES-1 mRNA was detected in 13.6 % of cases. In tumors, it was found in 60,6 % of cases. OY-TES-1 mRNA in the blood and in tumor of patients with CRC was detected statistically significantly more often at stages III and IV than at stages I and II (11,0 and 4,5 times, respectively), and also many times more often in tumors with a low degree of differentiation than with highly differentiated tumors. In patients with CRC, the OY-TES-1 mRNA in tumors with metastases in organs and lymph nodes was detected many times more often than in tumors without any metastases (by 16,4 and 17,4 times respectively).Conclusion. The data obtained indicate the absence of mRNA OY-TES-1gene in the blood of healthy individuals, the appearance of mRNA OY-TES-1 gene in the blood of CRC patients, and the possibility of using the detection of mRNA OY-TES-1 gene in the blood as an additional informative monitoring marker for colorectal cancer.

show abstract

Cancer‐testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis

Cited by 5 publications

References 24 publications

Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues

Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues

Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23

mRNA of the <i>OY-TES-1</i> gene in peripheral blood and tumors in colorectal cancer

Contact Info

Product

Resources

About